TEMPUS HLDGS Ltd

Tempus AI is highlighted as an AI healthcare diagnostics and data platform backed by a $446.3 million Cathie Wood stake. The company has amassed over 450 petabytes of clinical and genomic data, which supports its AI models and creates a competitive moat. Management is expanding into related diagnostics and says scaled ECG-based testing could eventually add more than $200 million in annual revenue. Analysts acknowledge TEM's potential but note other AI stocks may offer higher upside with lower downside risk. » Más en finance.yahoo.com

Tempus AI and Merck have agreed an expanded, multiyear collaboration under which Merck will use anonymized data as well as Tempus’s Lens platform and Workspaces environment. The aim is to accelerate biomarker discovery, identify resistance mechanisms and develop drug combinations in the early pipeline using AI and machine learning. Financial terms were not disclosed; Tempus recently filed its 2025 annual report with the SEC. » Más en de.investing.com